Try
REGENERON PHARMACEUTICALS, INC.
REGNUnited States
79 filed reports · 479 financial concepts · 41 earnings calls · 11 media appearances
Filed reports
79 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 278 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 38 | 226 | Dec 2016 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 31 | 4,411 | Jun 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 4,468 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 30, 2026 | 6 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 30, 2026 | 333 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 29, 2026 | 196 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 8, 2026 | 2 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 4, 2026 | 888 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Jan 30, 2026 | 6 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 28, 2025 | 251 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 6, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 1, 2025 | 130 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 29, 2025 | 134 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 5, 2025 | 420 | Open |
| FY2024 Q4 | 8-K | Dec 31, 2024 | Feb 4, 2025 | 6 | Open |
Financial data
479 concepts · 9,105 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial458 concepts · 8,131 facts · Dec 2007 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Costs and expenses57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Nonoperating income expense57 · Dec 2014 to Jun 2026
- Operating income loss57 · Dec 2014 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax57 · Dec 2014 to Jun 2026
- Research and development expense57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Adjustments to reconcile net income loss to cash provided by used in operating activities56 · Dec 2014 to Jun 2026
- Depreciation depletion and amortization56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in accounts receivable56 · Dec 2014 to Jun 2026
- Increase decrease in deferred income taxes56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets56 · Dec 2014 to Jun 2026
- Net cash provided by used in financing activities56 · Dec 2014 to Jun 2026
- Net cash provided by used in investing activities56 · Dec 2014 to Jun 2026
- Net cash provided by used in operating activities56 · Dec 2014 to Jun 2026
- Other noncash income expense56 · Dec 2014 to Jun 2026
- Payments related to tax withholding for share based compensation56 · Dec 2014 to Jun 2026
- Payments to acquire marketable securities56 · Dec 2014 to Jun 2026
Product5 concepts · 635 facts · Dec 2014 to Jun 2026
- Revenue510 · Dec 2014 to Jun 2026
- Cost of goods and services sold (US GAAP)94 · Dec 2016 to Jun 2026
- Revenue (excluding assessed tax)27 · Jun 2017 to Sep 2024
- Other operating income3 · Dec 2018 to Dec 2020
- Inventory write down1 · Dec 2021
Guidance11 concepts · 266 facts · Feb 2017 to Jul 2026
- Capital Expenditures Guidance84 · Feb 2017 to Jul 2026
- Effective Tax Rate Guidance80 · Feb 2017 to Jul 2026
- Gross Margin Guidance34 · Feb 2021 to Jul 2026
- Effective Tax Rate Guidance (Adjusted (non-GAAP))18 · Nov 2021 to Jul 2026
- Revenue Guidance12 · Jan 2018 to Nov 2019
- Gross Margin Guidance (on net product sales)10 · Nov 2021 to Aug 2023
- Gross Margin Guidance (on net product sales; Adjusted (non-GAAP))10 · Nov 2021 to Aug 2023
- EPS (Diluted) Guidance6 · Jul 2024 to Apr 2026
- Gross Margin Guidance (Adjusted (non-GAAP))4 · Feb 2023 to May 2024
- Gross Margin Guidance (net product sales)4 · Feb 2024 to Jul 2026
- Gross Margin Guidance (net product sales; Adjusted (non-GAAP))4 · Feb 2024 to Jul 2026
Geography3 concepts · 45 facts · Jun 2017 to Mar 2026
- Revenue (excluding assessed tax)23 · Jun 2017 to Mar 2026
- Revenue16 · Dec 2019 to Dec 2022
- Property, Plant & Equipment, Net6 · Dec 2017 to Dec 2019
Segment2 concepts · 28 facts · Dec 2022 to Jun 2026
- Reportable Segment14 · Dec 2022 to Jun 2026
- Research and development expense14 · Dec 2022 to Jun 2026
Segments
708 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis23 members · 603 facts
- Product114 · Dec 2016 to Jun 2026
- LIBTAYO Net Product Sales94 · Dec 2016 to Jun 2026
- Collaborationand Contract Manufacturing47 · Dec 2016 to Jun 2026
- Eylea Net Product Sales47 · Dec 2016 to Jun 2026
- Evkeeza33 · Dec 2019 to Jun 2026
- Product And Service Other33 · Dec 2019 to Jun 2026
- Arcalyst Net Product Sales31 · Dec 2016 to Dec 2023
- Collaboration Revenue31 · Mar 2020 to Jun 2026
- Praluent Net Product Sales31 · Jun 2020 to Jun 2026
- Inmazeb30 · Dec 2020 to Dec 2025
- REGENCOV20 · Dec 2018 to Dec 2023
- ELYEAHD17 · Dec 2021 to Dec 2025
- ELYEAHD And EYLEA17 · Dec 2021 to Dec 2025
- Libtayonet product sales12 · Dec 2018 to Sep 2022
- Other Products11 · Dec 2023 to Jun 2026
- Product and service other11 · Jun 2017 to Dec 2019
- EYLEAHD6 · Sep 2022 to Jun 2026
- EYLEAHD And EYLEA4 · Mar 2025 to Jun 2026
- Lynozyfic4 · Mar 2025 to Jun 2026
- Amounts Recognized In Connection With Up Front Payments3 · Dec 2018 to Dec 2020
- Inmazeb3 · Sep 2022 to Sep 2024
- Sanofi Collaboration Revenue3 · Dec 2020 to Dec 2022
- Collaboration revenue1 · Dec 2020
Statement geographical3 members · 45 facts
- Us26 · Jun 2017 to Mar 2026
- US16 · Dec 2019 to Dec 2022
- Europe3 · Dec 2017 to Dec 2019
Product or serviceus-gaap:ProductOrServiceAxis2 members · 32 facts
- Arcalyst Net Product Sales16 · Dec 2014 to Mar 2018
- Eylea Net Product Sales16 · Dec 2014 to Mar 2018
Statement business segments1 member · 28 facts
- Reportable28 · Dec 2022 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary185 claims from 15 reports · Sep 2024 to Oct 2026
- Management discussion (MD&A) commentary136 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes20 claims from 1 reports · Dec 2025
- Risk factors104 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · Aug 2016 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 30, 2026
- FY2026 Q1Apr 29, 2026
- FY2025 Q4Jan 30, 2026
- FY2025 Q3Oct 28, 2025
- FY2025 Q2Aug 1, 2025
- FY2025 Q1Apr 29, 2025
- FY2024 Q4Feb 4, 2025
- FY2024 Q3Oct 31, 2024
- FY2024 Q2Aug 1, 2024
- FY2024 Q1May 2, 2024
- FY2023 Q4Feb 2, 2024
- FY2023 Q3Nov 2, 2023
- FY2023 Q2Aug 3, 2023
- FY2023 Q1May 4, 2023
- FY2022 Q4Feb 3, 2023
- FY2022 Q3Nov 3, 2022
Executive media
11 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews8 · Jan 2020 to Jun 2025
- Other appearances2 · Oct 2025 to Apr 2026
- Conference talks1 · Jul 2020
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.